Inventor · disambiguated record
Che-Leung Law
Also filed as: LAW CHE · LAW CHE-LEUNG
30 granted patents·28 pending applications·3,632 citations·filing 1999–2023
98Inventor score
Top patents by PatentIndex Score
58 records- 0197US8067546B2Humanized anti-CD70 binding agents and uses thereofMCDONAGH CHARLOTTE·Filed 2006·Granted Nov 29, 2011·71 cites·25 claims
- 0297US7491390B2Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disordersSEATTLE GENETICS INC·Filed 2005·Granted Feb 17, 2009·60 cites·28 claims
- 0397US6905874B2Simultaneous stimulation and concentration of cellsXCYTE THERAPIES INC·Filed 2001·Granted Jun 14, 2005·950 cites·43 claims
- 0497US6867041B2Simultaneous stimulation and concentration of cellsXCYTE THERAPIES INC·Filed 2002·Granted Mar 15, 2005·935 cites·21 claims
- 0597US6797514B2Simultaneous stimulation and concentration of cellsXCYTE THERAPIES INC·Filed 2001·Granted Sep 28, 2004·985 cites·14 claims
- 0696US8337838B2Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disordersLAW CHE-LEUNG·Filed 2009·Granted Dec 25, 2012·30 cites·28 claims
- 0796US7572631B2Activation and expansion of T cellsINVITROGEN CORP·Filed 2005·Granted Aug 11, 2009·217 cites·7 claims
- 0895US8663642B2Anti-CD70 antibody-drug conjugates and their use for the treatment and prevention of cancer and immune disordersLAW CHE-LEUNG·Filed 2010·Granted Mar 4, 2014·44 cites·21 claims
- 0995US8609104B2Treatment of B-cell cancers with anti-CD70 antibody-drug conjugatesLAW CHE-LEUNG·Filed 2012·Granted Dec 17, 2013·27 cites·25 claims
- 1095US8562987B2Humanized anti-CD70 binding agents and uses thereofMCDONAGH CHARLOTTE·Filed 2011·Granted Oct 22, 2013·27 cites·24 claims
- 1195US7662387B2Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disordersSEATTLE GENETICS·Filed 2004·Granted Feb 16, 2010·142 cites·29 claims
- 1295US7641903B2Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disordersSEATTLE GENETICS INC·Filed 2007·Granted Jan 5, 2010·45 cites·22 claims
- 1394US9345785B2Treatment of renal cell carcinoma with anti-CD70 antibody-drug conjugatesLAW CHE-LEUNG·Filed 2009·Granted May 24, 2016·23 cites·34 claims
- 1493US9051372B2Anti-CD70 antibody and its use for the treatment of cancer and immune disordersLAW CHE-LEUNG·Filed 2008·Granted Jun 9, 2015·24 cites·12 claims
- 1593US8647624B2Treatment of immune disorders with anti-CD70 antibodyLAW CHE-LEUNG·Filed 2008·Granted Feb 11, 2014·21 cites·20 claims
- 1685US12496339B2Therapeutic vaccine for hepatitis b virus (HBV) using the HBV core antigenUNIV WASHINGTON·Filed 2023·Granted Dec 16, 2025·0 cites·10 claims
- 1785US11389532B2Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV PreS1 and/or PreS2, and/or s-HBsAg regions of the HBV envelope proteinUNIV WASHINGTON·Filed 2018·Granted Jul 19, 2022·2 cites·24 claims
- 1885US10201615B2Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathwaySEATTLE GENETICS INC·Filed 2016·Granted Feb 12, 2019·4 cites·21 claims
- 1983US12496353B2Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathwaySEAGEN INC·Filed 2023·Granted Dec 16, 2025·0 cites·13 claims
- 2083US9272052B2Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathwayLEWIS TIMOTHY S·Filed 2011·Granted Mar 1, 2016·8 cites·2 claims
- 2182US11202827B2Dosage and administration of non-fucosylated anti-CD40 antibodiesSEAGEN INC·Filed 2017·Granted Dec 21, 2021·2 cites·170 claims
- 2281US2024075134A1Dosage and administration of non-fucosylated anti-cd40 antibodySEAGEN INC·Filed 2023·Application pending·0 cites
- 2380US2024075135A1Dosage and administration of non-fucosylated anti-cd40 antibodiesSEAGEN INC·Filed 2023·Application pending·0 cites
- 2479US11324819B2Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigenUNIV WASHINGTON·Filed 2016·Granted May 10, 2022·1 cites·16 claims
- 2579US7541184B2Activation and expansion of cellsINVITROGEN CORP·Filed 2004·Granted Jun 2, 2009·10 cites·2 claims
- 2679US2023201344A1Dosage and administration of non-fucosylated anti-cd40 antibodySEAGEN INC·Filed 2022·Application pending·0 cites
- 2778US12285482B2Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope proteinUNIV WASHINGTON·Filed 2022·Granted Apr 29, 2025·0 cites·20 claims
- 2878US2023201343A1Dosage and administration of non-fucosylated anti-cd40 antibodiesSEAGEN INC·Filed 2022·Application pending·0 cites
- 2978US2023105802A1Anti-ntb-a antibodies and related compositions and methodsSEAGEN INC·Filed 2022·Application pending·0 cites
- 3078US2022265822A1Dosage and administration of non-fucosylated anti-cd40 antibodySEAGEN INC·Filed 2022·Application pending·0 cites
- 3177US11883488B2Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV core antigenUNIV WASHINGTON·Filed 2022·Granted Jan 30, 2024·0 cites·21 claims
- 3277US11607460B2Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathwaySEATTLE GENETICS INC·Filed 2018·Granted Mar 21, 2023·1 cites·12 claims
- 3377US9708404B2Anti-NTB-A antibodies and related compositions and methodsSEATTLE GENETICS INC·Filed 2013·Granted Jul 18, 2017·2 cites·12 claims
- 3477US2022249662A1Dosage and administration of non-fucosylated anti-cd40 antibodiesSEAGEN INC·Filed 2022·Application pending·0 cites
- 3576US10435468B2Anti-NTB-A antibodies and related compositions and methodsSEATTLE GENETICS INC·Filed 2017·Granted Oct 8, 2019·1 cites·5 claims
- 3670US2023218776A1Anti-ntb-a antibodies and related compositions and methodsSEAGEN INC·Filed 2022·Application pending·0 cites
- 3767US2010183636A1Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disordersSEATTLE GENETICS INC·Filed 2009·Application pending·0 cites
- 3864US2008025989A1Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disordersSEATTLE GENETICS INC·Filed 2007·Application pending·0 cites
- 3962US2005153447A1Activation and expansion of cellsXCYTE THERAPIES INC·Filed 2004·Application pending·0 cites
- 4062US2019375841A1Anti-ntb-a antibodies and related compositions and methodsSEATTLE GENETICS INC·Filed 2019·Application pending·0 cites
- 4162US2024084035A1Combination therapy with immune cell engaging proteins and immunomodulatorsHARPOON THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4262US2005214942A1Activation and expansion of cellsXCYTE THERAPIES INC·Filed 2004·Application pending·0 cites
- 4362US2010129362A1Treatment of psoriatic arthritis with anti-cd70 antibodySEATTLE GENETICS INC·Filed 2009·Application pending·0 cites
- 4460US11213584B2Dosage and administration of non-fucosylated anti-CD40 antibodiesSEAGEN INC·Filed 2015·Granted Jan 4, 2022·0 cites·46 claims
- 4559US2004253250A1Compositions and methods for regulating lymphocyte activationXCYTE THERAPIES INC·Filed 2003·Application pending·0 cites
- 4656US11351269B2Anti-NTB-A antibodies and related compositions and methodsSEAGEN INC·Filed 2016·Granted Jun 7, 2022·0 cites·90 claims
- 4756US2003119185A1Activation and expansion of cellsXCYTE THERAPIES INC·Filed 2002·Application pending·0 cites
- 4851US2005261478A1Compositions and methods for regulating lymphocyte activationXCYTE THERAPIES INC·Filed 2005·Application pending·0 cites
- 4946US2006121476A1Cancer associated antigens, sga-56m and sga-56mv, and uses thereofSEATTLE GENETICS INC·Filed 2003·Application pending·0 cites
- 5045US2007128593A1Sga-1m, a cancer associated antigen, and uses thereofSEATTLE GENETICS INC·Filed 2003·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Che-Leung Law files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →